Cargando…

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Detalles Bibliográficos
Autores principales:	Liu, David, Schilling, Bastian, Liu, Derek, Sucker, Antje, Livingstone, Elisabeth, Jerby-Arnon, Livnat, Zimmer, Lisa, Gutzmer, Ralf, Satzger, Imke, Loquai, Carmen, Grabbe, Stephan, Vokes, Natalie, Margolis, Claire A., Conway, Jake, He, Meng Xiao, Elmarakeby, Haitham, Dietlein, Felix, Miao, Diana, Tracy, Adam, Gogas, Helen, Goldinger, Simone M., Utikal, Jochen, Blank, Christian U., Rauschenberg, Ricarda, von Bubnoff, Dagmar, Krackhardt, Angela, Weide, Benjamin, Haferkamp, Sebastian, Kiecker, Felix, Izar, Ben, Garraway, Levi, Regev, Aviv, Flaherty, Keith, Paschen, Annette, Van Allen, Eliezer M., Schadendorf, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2020
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358200/ https://www.ncbi.nlm.nih.gov/pubmed/32561875 http://dx.doi.org/10.1038/s41591-020-0975-4

Ejemplares similares

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
por: Liu, David, et al.
Publicado: (2019)

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
por: Hecht, Markus, et al.
Publicado: (2018)

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
por: Sucker, Antje, et al.
Publicado: (2017)

DIALOGUE maps multicellular programs in tissue from single-cell or spatial transcriptomics data
por: Jerby-Arnon, Livnat, et al.
Publicado: (2022)

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
por: Berking, Carola, et al.
Publicado: (2023)

Moving ahead on harnessing synthetic lethality to fight cancer
por: Jerby-Arnon, Livnat, et al.
Publicado: (2015)

Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients
por: Schaefer, Tim, et al.
Publicado: (2017)

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Willingness to pay for a cure of low-risk melanoma patients in Germany
por: Augustin, Matthias, et al.
Publicado: (2018)

Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism
por: Jerby, Livnat, et al.
Publicado: (2010)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians
por: Kähler, Katharina C., et al.
Publicado: (2018)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis
por: Gutzmer, Ralf, et al.
Publicado: (2021)

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
por: Haist, Maximilian, et al.
Publicado: (2022)

Long-lasting tumor response on short-time administration of vemurafenib—A case report
por: Mitzel, Heidrun, et al.
Publicado: (2014)

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
por: Hassel, Jessica C., et al.
Publicado: (2017)

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
por: Voskens, Caroline J., et al.
Publicado: (2013)

Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook
por: Möhn, Nora, et al.
Publicado: (2019)

Predicting selective drug targets in cancer through metabolic networks
por: Folger, Ori, et al.
Publicado: (2011)

Predicting selective drug targets in cancer through metabolic networks
por: Folger, Ori, et al.
Publicado: (2011)

Predicting selective drug targets in cancer through metabolic networks
por: Folger, Ori, et al.
Publicado: (2011)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
por: Haist, Maximilian, et al.
Publicado: (2023)

Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy
por: Kaehler, Katharina C., et al.
Publicado: (2016)

Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation
por: Gräger, Nikolai, et al.
Publicado: (2019)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
por: Thier, Beatrice, et al.
Publicado: (2022)

Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies
por: Wagner, Nikolaus B., et al.
Publicado: (2019)

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
por: Satzger, I, et al.
Publicado: (2008)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS
por: KAATZ, Martin, et al.
Publicado: (2022)

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
por: Malvehy, Josep, et al.
Publicado: (2021)

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
por: Ugurel, Selma, et al.
Publicado: (2017)

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
por: Knispel, Sarah, et al.
Publicado: (2020)

Medikamentöse Therapie des inoperablen Melanoms
por: Lodde, Georg, et al.
Publicado: (2023)

Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells
por: Bauer, Daniel, et al.
Publicado: (2017)

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
por: Stege, H. M., et al.
Publicado: (2021)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8tilphkaf9p4frt0a8mlsr3105